Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis.

Faner R, Morrow JD, Casas-Recasens S, Cloonan SM, Noell G, López-Giraldo A, Tal-Singer R, Miller BE, Silverman EK, Agustí A, Hersh CP.

Respir Res. 2019 Jan 8;20(1):5. doi: 10.1186/s12931-018-0965-y.

2.

Building Strong Neighbourhoods in the Lung with a Little Help from my MSCs.

Faner R, Rojas M.

Am J Respir Crit Care Med. 2018 Dec 17. doi: 10.1164/rccm.201811-2153ED. [Epub ahead of print] No abstract available.

PMID:
30557513
3.

Determinants of the Appearance and Progression of Early-Onset Chronic Obstructive Pulmonary Disease in Young Adults. A Case-Control Study with Follow-up.

Borràs-Santos A, Garcia-Aymerich J, Soler-Cataluña JJ, Vigil Giménez L, Gea Guiral J, Rodríguez Chiaradía D, Pascual-Guardia S, Marcos Rodríguez PJ, Alvarez Martinez CJ, Casanova Macario C, López-Campos JL, Carrasco Hernández L, Martínez-González C, Santos-Pérez S, Peces-Barba G, Molina Paris J, Román Rodríguez M, Barberà JA, Faner R, Agustí A, Cosío BG; en representación del Grupo Investigador del estudio EARLY COPD.

Arch Bronconeumol. 2018 Nov 11. pii: S0300-2896(18)30341-7. doi: 10.1016/j.arbres.2018.09.007. [Epub ahead of print] English, Spanish.

4.

The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease.

Gea J, Pascual S, Castro-Acosta A, Hernández-Carcereny C, Castelo R, Márquez-Martín E, Montón C, Palou A, Faner R, Furlong LI, Seijo L, Sanz F, Torà M, Vilaplana C, Casadevall C, López-Campos JL, Monsó E, Peces-Barba G, Cosío BG, Agustí A; en representación del grupo BIOMEPOC; Anexo. Miembros del grupo BIOMEPOC.

Arch Bronconeumol. 2018 Oct 18. pii: S0300-2896(18)30329-6. doi: 10.1016/j.arbres.2018.07.026. [Epub ahead of print] English, Spanish.

5.

The Overlap of Lung Tissue Transcriptome of Smoke Exposed Mice with Human Smoking and COPD.

Obeidat M, Dvorkin-Gheva A, Li X, Bossé Y, Brandsma CA, Nickle DC, Hansbro PM, Faner R, Agusti A, Paré PD, Stampfli MR, Sin DD.

Sci Rep. 2018 Aug 8;8(1):11881. doi: 10.1038/s41598-018-30313-z.

6.

Characterization, localization and comparison of c-Kit+ lung cells in never smokers and smokers with and without COPD.

López-Giraldo A, Cruz T, Molins L, Guirao Á, Saco A, Cuerpo S, Ramirez J, Agustí Á, Faner R.

BMC Pulm Med. 2018 Jul 31;18(1):123. doi: 10.1186/s12890-018-0688-3.

7.

Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort.

Faner R, Noell G, Badia JR, López-Giraldo A, Bakke P, Silverman EK, Tal-Singer R, Agustí A.

Respir Med. 2018 Aug;141:14-19. doi: 10.1016/j.rmed.2018.06.015. Epub 2018 Jun 19.

PMID:
30053959
8.

Precision medicine in COPD exacerbations.

Agusti A, Faner R, Celli B, Rodriguez-Roisin R.

Lancet Respir Med. 2018 Sep;6(9):657-659. doi: 10.1016/S2213-2600(18)30296-0. Epub 2018 Jul 18. No abstract available.

PMID:
30029970
9.

How to Define Early Chronic Obstructive Pulmonary Disease.

Agusti A, Faner R.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):973. doi: 10.1164/rccm.201805-0880LE. No abstract available.

10.

Bone marrow characterization in COPD: a multi-level network analysis.

Toledo-Pons N, Noell G, Jahn A, Iglesias A, Duran MA, Iglesias J, Rios A, Scrimini S, Faner R, Gigirey O, Agustí A, Cosío BG.

Respir Res. 2018 Jun 15;19(1):118. doi: 10.1186/s12931-018-0824-x.

11.

The Changing Landscape of Chronic Obstructive Pulmonary Disease.

Agustí A, Faner R.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):978-981. doi: 10.1164/rccm.201804-0714ED. No abstract available.

PMID:
29701997
12.

COPD beyond smoking: new paradigm, novel opportunities.

Agustí A, Faner R.

Lancet Respir Med. 2018 May;6(5):324-326. doi: 10.1016/S2213-2600(18)30060-2. Epub 2018 Feb 26. No abstract available.

PMID:
29496484
13.

Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.

Celli BR, Locantore N, Tal-Singer R, Riley J, Miller B, Vestbo J, Yates JC, Silverman EK, Owen CA, Divo M, Pinto-Plata V, Wouters EFM, Faner R, Agusti A; ECLIPSE Study Investigators.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702146. doi: 10.1183/13993003.02146-2017. Print 2018 Feb.

PMID:
29437944
14.

From systems biology to P4 medicine: applications in respiratory medicine.

Noell G, Faner R, Agustí A.

Eur Respir Rev. 2018 Feb 7;27(147). pii: 170110. doi: 10.1183/16000617.0110-2017. Print 2018 Mar 31. Review.

15.

Hospitalizations due to exacerbations of COPD: A big data perspective.

Serra-Picamal X, Roman R, Escarrabill J, García-Altés A, Argimón JM, Soler N, Faner R, Carbonell EM, Trilla A, Agusti A.

Respir Med. 2018 Dec;145:219-225. doi: 10.1016/j.rmed.2018.01.008. Epub 2018 Jan 16.

PMID:
29398283
16.

Clinical News.

Hosgood S, Williams R, Brugada J, Agusti A, Faner R, Noell G.

Br J Hosp Med (Lond). 2018 Jan 2;79(1):8-11. doi: 10.12968/hmed.2018.79.1.8. No abstract available.

PMID:
29315044
17.

Towards a global initiative for fibrosis treatment (GIFT).

Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, Antoniou KM, Sellares J.

ERJ Open Res. 2017 Dec 1;3(4). pii: 00106-2017. doi: 10.1183/23120541.00106-2017. eCollection 2017 Oct.

18.

Lung function in early adulthood and health in later life: a transgenerational cohort analysis.

Agustí A, Noell G, Brugada J, Faner R.

Lancet Respir Med. 2017 Dec;5(12):935-945. doi: 10.1016/S2213-2600(17)30434-4. Epub 2017 Nov 14.

PMID:
29150410
19.

COPD: algorithms and clinical management.

Faner R, Agustí A.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701733. doi: 10.1183/13993003.01733-2017. Print 2017 Nov. No abstract available.

PMID:
29097436
20.

Precision medicine in airway diseases: moving to clinical practice.

Agustí A, Bafadhel M, Beasley R, Bel EH, Faner R, Gibson PG, Louis R, McDonald VM, Sterk PJ, Thomas M, Vogelmeier C, Pavord ID; on behalf of all participants in the seminar.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701655. doi: 10.1183/13993003.01655-2017. Print 2017 Oct.

PMID:
29051276
21.

The EASI model: A first integrative computational approximation to the natural history of COPD.

Agustí A, Compte A, Faner R, Garcia-Aymerich J, Noell G, Cosio BG, Rodriguez-Roisin R, Celli B, Anto JM.

PLoS One. 2017 Oct 10;12(10):e0185502. doi: 10.1371/journal.pone.0185502. eCollection 2017.

22.

Multi-level differential network analysis of COPD exacerbations.

Noell G, Cosío BG, Faner R, Monsó E, Peces-Barba G, de Diego A, Esteban C, Gea J, Rodriguez-Roisin R, Garcia-Nuñez M, Pozo-Rodriguez F, Kalko SG, Agustí A.

Eur Respir J. 2017 Sep 27;50(3). pii: 1700075. doi: 10.1183/13993003.00075-2017. Print 2017 Sep.

PMID:
28954781
23.

What does endotyping mean for treatment in chronic obstructive pulmonary disease?

Agustí A, Celli B, Faner R.

Lancet. 2017 Sep 2;390(10098):980-987. doi: 10.1016/S0140-6736(17)32136-0. Review.

PMID:
28872030
24.

Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers.

Obeidat M, Nie Y, Fishbane N, Li X, Bossé Y, Joubert P, Nickle DC, Hao K, Postma DS, Timens W, Sze MA, Shannon CP, Hollander Z, Ng RT, McManus B, Miller BE, Rennard S, Spira A, Hackett TL, Lam W, Lam S, Faner R, Agusti A, Hogg JC, Sin DD, Paré PD.

Am J Respir Cell Mol Biol. 2017 Oct;57(4):411-418. doi: 10.1165/rcmb.2016-0284OC.

25.

The microbiome in respiratory medicine: current challenges and future perspectives.

Faner R, Sibila O, Agustí A, Bernasconi E, Chalmers JD, Huffnagle GB, Manichanh C, Molyneaux PL, Paredes R, Pérez Brocal V, Ponomarenko J, Sethi S, Dorca J, Monsó E.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602086. doi: 10.1183/13993003.02086-2016. Print 2017 Apr. Review.

26.

Modified mesenchymal stem cells using miRNA transduction alter lung injury in a bleomycin model.

Huleihel L, Sellares J, Cardenes N, Álvarez D, Faner R, Sakamoto K, Yu G, Kapetanaki MG, Kaminski N, Rojas M.

Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L92-L103. doi: 10.1152/ajplung.00323.2016. Epub 2017 Apr 6.

27.

Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.

Faner R, Agustí Á.

Ann Am Thorac Soc. 2016 Dec;13 Suppl 2:S466-S470. doi: 10.1513/AnnalsATS.201605-372AW. Review.

PMID:
28005422
28.

The inflammasome pathway in stable COPD and acute exacerbations.

Faner R, Sobradillo P, Noguera A, Gomez C, Cruz T, López-Giraldo A, Ballester E, Soler N, Arostegui JI, Pelegrín P, Rodriguez-Roisin R, Yagüe J, Cosio BG, Juan M, Agustí A.

ERJ Open Res. 2016 Jul 11;2(3). pii: 00002-2016. eCollection 2016 Jul.

29.

Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema.

Faner R, Cruz T, Casserras T, López-Giraldo A, Noell G, Coca I, Tal-Singer R, Miller B, Rodriguez-Roisin R, Spira A, Kalko SG, Agustí A.

Am J Respir Crit Care Med. 2016 Jun 1;193(11):1242-53. doi: 10.1164/rccm.201507-1311OC.

PMID:
26735770
30.

Network analysis: a way forward for understanding COPD multimorbidity.

Faner R, Agustí A.

Eur Respir J. 2015 Sep;46(3):591-2. doi: 10.1183/09031936.00054815. No abstract available.

31.

Molecular and clinical diseasome of comorbidities in exacerbated COPD patients.

Faner R, Gutiérrez-Sacristán A, Castro-Acosta A, Grosdidier S, Gan W, Sánchez-Mayor M, Lopez-Campos JL, Pozo-Rodriguez F, Sanz F, Mannino D, Furlong LI, Agusti A.

Eur Respir J. 2015 Oct;46(4):1001-10. doi: 10.1183/13993003.00763-2015. Epub 2015 Aug 6.

32.

Biomarkers, the control panel and personalized COPD medicine.

Agusti A, Gea J, Faner R.

Respirology. 2016 Jan;21(1):24-33. doi: 10.1111/resp.12585. Epub 2015 Jul 14. Review.

33.

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J.

N Engl J Med. 2015 Jul 9;373(2):111-22. doi: 10.1056/NEJMoa1411532.

34.

Fibrinogen and COPD: Now what?

Faner R, Agusti A.

Chronic Obstr Pulm Dis. 2015 Jan 24;2(1):1-3. doi: 10.15326/jcopdf.2.1.2014.0127. No abstract available.

35.

Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Agustí A, Antó JM, Auffray C, Barbé F, Barreiro E, Dorca J, Escarrabill J, Faner R, Furlong LI, Garcia-Aymerich J, Gea J, Lindmark B, Monsó E, Plaza V, Puhan MA, Roca J, Ruiz-Manzano J, Sampietro-Colom L, Sanz F, Serrano L, Sharpe J, Sibila O, Silverman EK, Sterk PJ, Sznajder JI.

Am J Respir Crit Care Med. 2015 Feb 15;191(4):391-401. doi: 10.1164/rccm.201410-1935PP.

36.

HLA-DQ2/DQ8 and HLA-DQB1*02 homozygosity typing by real-time polymerase chain reaction for the assessment of celiac disease genetic risk: evaluation of a Spanish celiac population.

Ruiz-Ortiz E, Montraveta M, Cabré E, Herrero-Mata MJ, Pujol-Borrell R, Palou E, Faner R.

Tissue Antigens. 2014 Dec;84(6):545-53. doi: 10.1111/tan.12472.

PMID:
25413104
37.

Network medicine analysis of COPD multimorbidities.

Grosdidier S, Ferrer A, Faner R, Piñero J, Roca J, Cosío B, Agustí A, Gea J, Sanz F, Furlong LI.

Respir Res. 2014 Sep 24;15:111. doi: 10.1186/s12931-014-0111-4.

38.

Network medicine, multimorbidity and the lung in the elderly.

Faner R, Cruz T, López-Giraldo A, Agustí A.

Eur Respir J. 2014 Sep;44(3):775-88. doi: 10.1183/09031936.00078714. Epub 2014 Jul 25. Review.

39.

Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect.

Faner R, Gonzalez N, Cruz T, Kalko SG, Agustí A.

PLoS One. 2014 May 15;9(5):e97491. doi: 10.1371/journal.pone.0097491. eCollection 2014.

40.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators.

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5. Review.

PMID:
24310110
41.

Immune response in chronic obstructive pulmonary disease.

Faner R, Cruz T, Agusti A.

Expert Rev Clin Immunol. 2013 Sep;9(9):821-33. doi: 10.1586/1744666X.2013.828875. Review.

PMID:
24070046
42.

HLA distribution in COPD patients.

Faner R, Nuñez B, Sauleda J, Garcia-Aymerich J, Pons J, Crespí C, Milà J, González JR, Maria Antó J, Agusti A; PAC-COPD Study Group.

COPD. 2013 Apr;10(2):138-46. doi: 10.3109/15412555.2012.729621. Epub 2013 Mar 20.

PMID:
23514216
43.

An investigation of the resolution of inflammation (catabasis) in COPD.

Noguera A, Gomez C, Faner R, Cosio B, González-Périz A, Clària J, Carvajal A, Agustí A.

Respir Res. 2012 Nov 13;13:101. doi: 10.1186/1465-9921-13-101.

44.

Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Faner R, Rojas M, Macnee W, Agustí A.

Am J Respir Crit Care Med. 2012 Aug 15;186(4):306-13. doi: 10.1164/rccm.201202-0282PP. Epub 2012 May 10. Review.

PMID:
22582162
45.

Systemic inflammation and comorbidities in chronic obstructive pulmonary disease.

Agustí A, Faner R.

Proc Am Thorac Soc. 2012 May;9(2):43-6. doi: 10.1513/pats.201108-050MS. Review.

PMID:
22550240
46.

Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance.

Colobran R, Armengol Mdel P, Faner R, Gärtner M, Tykocinski LO, Lucas A, Ruiz M, Juan M, Kyewski B, Pujol-Borrell R.

Hum Mol Genet. 2011 Sep 1;20(17):3415-23. doi: 10.1093/hmg/ddr247. Epub 2011 Jun 3.

PMID:
21642385
47.

CCL4L polymorphisms and CCL4/CCL4L serum levels are associated with psoriasis severity.

Pedrosa E, Carretero-Iglesia L, Boada A, Colobran R, Faner R, Pujol-Autonell I, Palou E, Esteve A, Pujol-Borrell R, Ferrándiz C, Juan M, Carrascosa JM.

J Invest Dermatol. 2011 Sep;131(9):1830-7. doi: 10.1038/jid.2011.127. Epub 2011 May 26.

48.

ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression.

Ballana E, Senserrich J, Pauls E, Faner R, Mercader JM, Uyttebroeck F, Palou E, Mena MP, Grau E, Clotet B, Ruiz L, Telenti A, Ciuffi A, Esté JA.

Clin Infect Dis. 2010 Apr 1;50(7):1022-32. doi: 10.1086/651114.

PMID:
20192730
49.

Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Faner R, James E, Huston L, Pujol-Borrel R, Kwok WW, Juan M.

Eur J Immunol. 2010 Jan;40(1):91-102. doi: 10.1002/eji.200939225.

50.

High resolution definition of HLA-DRB haplotypes by a simplified microsatellite typing technique.

Doxiadis GG, de Groot N, Dauber EM, van Eede PH, Fae I, Faner R, Fischer G, Grubic Z, Lardy NM, Mayr W, Palou E, Swelsen W, Stingl K, Doxiadis II, Bontrop RE.

Tissue Antigens. 2009 Dec;74(6):486-93. doi: 10.1111/j.1399-0039.2009.01369.x. Epub 2009 Sep 24.

PMID:
19778321

Supplemental Content

Support Center